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ABSTRACT (English Version) 
Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine 
phosphatases and is involved in the regulation of cell homeostasis through the 
negative regulation of signaling pathways initiated by protein kinases. As several 
cancers are characterized by the aberrant activity of oncogenic kinases, it was not 
surprising that a phosphatase like PP2A has progressively been considered as a 
potential tumor suppressor. Indeed, multiple solid tumors (e.g. melanomas, 
colorectal carcinomas, lung and breast cancers) present with genetic and/ or 
functional inactivation of different PP2A subunits and, therefore, loss of PP2A 
phosphatase activity towards certain substrates. Likewise, impaired PP2A 
phosphatase activity has been linked to B-cell chronic lymphocytic leukemia, 
Philadelphia-chromosome positive acute lymphoblastic leukemia and blast crisis 
chronic myeloid leukemia (CML). In CML the deregulated tyrosine kinase activity of 
p210-BCR/ABL oncoproteins is sufficient to induce and sustain the leukemic 
phenotype, and contributes to disease progression. Imatinib mesylate, a BCR/ABL 
kinase inhibitor, is effective in most of chronic phase CML patients. However, a 
significant percentage of CML patients develop resistance to imatinib and/or still 
progresses to blast crisis, a disease stage that is often refractory to imatinib 
therapy. Furthermore, there is compelling evidence indicating that the CML 
leukemia stem cell is also resistant to imatinib. We have recently reported that the 
phosphatase activity of PP2A is markedly inhibited in blast crisis and, to a lesser 
extent, chronic phase CML patient cells and that pharmacologic re-activation of 
PP2A phosphatase activity by activating drugs such as Forskolin and FTY720 led 
to growth suppression, enhanced apoptosis impaired clonogenic potential and 
decreased in vivo leukemogenesis of imatinib-sensitive and  
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-resistant CML-BC and CML-CP patient. Furthermore we have evidence that PP2A 
inactivation is an event that occurs also at the level of the leukemic stem cell and 
that PP2A re-activation hampers the survival and self-renewal of CML stem cells 
and possibly overcome the resistance of CML quiescent stem cells to tyrosine 
kinase inhibitor monotherapy.  Thus, inducing PP2A phosphatase activity has the 
potential to eradicate CML by efficiently targeting both leukemic stem and 
progenitor cells regardless of their degree of sensitivity to kinase. Therefore, the 
combination of PP2A phosphatase-activating and BCR/ABL kinase-inhibiting drugs 
may represent a powerful therapeutic strategy for CML patients. 
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ABSTRACT (Italian Version) 
La protein phosphatase-2A (PP2A), una delle principali serin-treonin 
fosfatasi, è coinvolta nella regolazione dell’omeostasi cellulare, attraverso il 
controllo negativo di pathways protein-chinasi dipendenti. Molti tumori sono 
caratterizzati dall’espressione di oncogeni ad attività chinasica costitutiva, pertanto 
non sorprende che una fosfatasi come PP2A sia sempre più spesso descritta 
come onco-soppressore. In effetti, molti tumori solidi (melanoma, carcinomi del 
colon, del polmone e della mammella) presentano alterazioni genetiche e/o 
funzionali di diverse subunità di PP2A, con conseguente perdita della sua attività 
fosfatasica verso substrati specifici. Inoltre, l’alterazione dell’attivita’ di PP2A è 
stata collegata alla leucemia linfatica cronica di tipo B, alla leucemia linfoblastica 
acuta e alla leucemia mieloide cronica (LMC). Nella LMC l'attività costitutiva della 
tirosin-chinasi p210-BCR/ABL è sufficiente per indurre e sostenere il fenotipo 
leucemico e contribuisce alla progressione della neoplasia. L’Imatinib mesilato, un 
inibitore dell’attivita’ chinasica di BCR/ABL, è efficace nella maggior parte dei 
pazienti nella fase cronica della LMC. Tuttavia, una percentuale significativa dei 
pazienti con LMC sviluppa resistenza a Imatinib e/o progredisce verso la crisi 
blastica, fase della malattia che spesso risulta refrattaria alla terapia; inoltre dati 
recenti sembrano mettere in evidenza lo sviluppo di resistenza all’Imatinib da parte 
della cellula staminale leucemica della LMC. Recentemente abbiamo dimostrato 
che l’attività di PP2A è inibita sia nella fase di crisi blastica, sia, seppur in minor 
misura, nella fase cronica; inoltre, l’utilizzo di farmaci come Forskolin e FTY7220 
porta alla riattivazione farmacologica di PP2A, provocando l’inibizione della 
proliferazione e del potenziale clonogenico, nonchè l’induzione dell’apoptosi in 
cellule di pazienti in fase cronica e in crisi blastica suscettibili o resistenti 
all’Imatinib. Dati preliminari dimostrano che l’inattivazione di PP2A avviene anche 
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a livello della cellula staminale leucemica e che la sua riattivazione ne inibisce la 
sopravvivenza e il self-renewal; tale approccio, potrebbe rappresentare una 
strategia per superare la farmaco-resistenza a inibitori dell’attività chinasica di 
BCR/ABL. Quindi, l’induzione dell’attivazione di PP2A attraverso il targeting sia dei 
progenitori che delle cellule staminali leucemiche ha il potenziale di eradicare la 
LMC. La combinazione di farmaci attivatori di PP2A e di inibitori di BCR/ABL 
potrebbe rappresentare una nuova strategia terapeutica per i pazienti affetti da 
LMC. 
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INTRODUCTION 
The ability to balance a complex network of signal transduction pathways is 
a key element in the normal homeostasis of a cell. Survival, proliferation and 
differentiation signals must be tightly controlled in order for a eukaryotic cell to 
keep its place in a multicellular organism and accurately react to external stimuli 
whether by proliferating, differentiating or eventually dying. Genetic or functional 
alterations of specific cell components may lead to inadequate responses to the 
microenvironment and therefore aberrant activation of pathways that control cell 
proliferation, survival and differentiation, ultimately leading to tumorigenesis and 
cancer (1). Mutations, amplifications or rearrangements may lead to the 
uncontrolled activity of proteins encoded by so-called proto-oncogenes (2), which 
are frequently cell cycle-promoting and/or apoptosis-repressing factors. This is 
often associated with the genetic or functional loss of tumor suppressor proteins, 
which usually have cell cycle-repressing and/or apoptosis-promoting effects (3). 
Gain of oncogene function associated with loss of tumor suppressors is now widely 
recognized as a hallmark of cancer initiation and progression (4). 
One primary mechanism by which a normal cell maintains the balance of 
tumor-inducing and tumor-suppressing signals and appropriately responds to 
extracellular stimuli is reversible protein phosphorylation (5). Signals from the 
microenvironment (i.e. hormones and growth factors) are detected by cell surface 
receptors and translated into the activation of protein kinases which, in turn, act by 
phosphorylating substrates, thereby inducing an intracellular signal transduction 
cascade that directly affects the physiological response of the cell to external 
stimuli. The reversal of protein phosphorylation by protein phosphatases is 
essential in order to preserve correct cell physiology and tightly regulate these 
important signal transduction pathways. Given this scenario, it comes as no 
surprise that the majority of oncogenes identified thus far encode protein kinases, 
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and that aberrant regulation of their activity plays a major role in the induction of a 
cancerous phenotype (6). 
Some of the best known examples of oncoproteins with unrestrained kinase 
activity are products of the t(9;22) translocation: the BCR/ABL oncoproteins, which 
are the driving force in the induction of both chronic myeloid leukemia (CML) and 
Philadelphia-positive acute lymphoblastic leukemia (Ph-ALL) (7, 8). Conversely, it 
seems logical to assume that protein phosphatases may also play a key role in 
cancer progression by acting as important regulators of the activation status of 
proteins involved in signal transduction. Undeniably, the study of protein 
phosphatases and their regulation has become an expanding field of research 
aimed at shedding light on the importance of these proteins in cancer (9). In 
particular, protein phosphatase 2A (PP2A) has been the subject of recent 
investigations that have begun to unravel the central role of this enzyme in cancer. 
By negatively regulating many of the signals triggered by oncogenic kinases, PP2A 
can be truly described as a tumor suppressor (10, 11). 
Protein phosphatase 2A 
PP2A is one of the major serine-threonine phosphatases. Highly conserved 
and ubiquitously expressed, PP2A is directly involved in a multitude of cellular 
processes by dephosphorylating specific substrates, therefore providing a negative 
feedback to signals initiated by protein kinases. PP2A phosphatase activity has 
been linked to the regulation of the cell cycle, signal transduction, DNA replication, 
transcription and translation (12, 13); for that reason, a peculiarity of PP2A is that a 
single phosphatase is responsible for regulating a variety of processes triggered by 
an array of different protein kinases. The ability of PP2A to affect the 
phosphorylation status of a wide variety of substrates is a consequence of its 
complex structure and regulation (Figure 1). PP2A is a heterodimeric or 
 8
heterotrimeric complex which contains a constant core dimeric structure, a 36 kDa 
catalytic subunit (PP2Ac, α and β isoforms) and a 65 kDa structural subunit 
(PP2A/A or PR65, α and β isoforms); this dimeric structure (PP2A/AC) may or may 
not be associated with a variable third subunit, a family of regulatory B subunits 
that provide substrate/tissue specificity and which are also differentially expressed 
during development (13, 14) (Figure 1). The B subunits are classified into four 
different families of unrelated proteins: PR55/B (four isoforms), PR61/B′ (encoded 
by five genes with up to eleven isoforms), PR72/B′′ (four isoforms) and 
PR93/110/B′′′ (two unrelated proteins) (14). The ability of PP2A to function as a 
dimer and also associate with an array of more than twenty interchangeable B 
subunits partially explains the variety of functions carried by this enzyme and 
underlines the potential complexity of PP2A phosphatase activity and its 
regulation. Thus, it seems logical that specific heterotrimeric configurations are 
Figure 1: Schematic representation of the quaternary structure of the PP2A holoenzyme. The figure shows the different levels at 
which the enzyme can be modulated either by changing the dimeric/trimeric composition, post-translational modifications and/or 
regulation by inhibitory molecules 
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responsible for different PP2A functions. As an example, it has been found that 
PR55/B may regulate cytokinesis in yeast (15), correct segregation of chromatids 
in Drosophila (16) and neuronal differentiation in humans (17); the B′ subunit family 
appears to be important for regulating the formation of cyclin-G/PP2A complexes, 
which regulate the phosphorylation status of mdm2, indirectly affecting the stability 
of p53 (18); PR59/B’’ targets PP2A to dephosphorylate the retinoblastoma-related 
p107 protein, suggesting a role in the regulation of the cell cycle (19). Such a 
variety of forms and activities places PP2A at the center of the regulation of most 
signal transduction pathways triggered and sustained by protein kinases. As an 
example, PP2A can dephosphorylate and inactivate MEK1 and ERK-family 
kinases, therefore inhibiting mitogenic signals (20). Moreover the small-t antigen, a 
viral protein that is involved in cellular transformation, is believed to cooperate with 
the large-T antigen of the SV40 virus in inducing transformation and 
immortalization of target cells in part by hyper-activating the MAPK pathway as a 
consequence of the displacement of the variable B subunit which results in PP2A 
inactivation (21). Furthermore, a direct involvement of PP2A in the regulation of the 
cell cycle has been reported at many different levels. Specifically, the 
PR55/Bα:PP2A complex dephosphorylates and inhibits CAK (Cdk-activating 
kinase) that, when active, phosphorylates and activates Cdc2 in the MPF complex 
(M-phase-promoting factor) therefore inducing the G2/M transition (22). In this 
instance PP2A is able to exert a negative effect on regulating entry into mitosis. On 
the other hand, PP2A has a positive regulatory function in apoptosis (23); this is 
mediated by dephosphorylation and inactivation of the anti-apoptotic Bcl-2 protein 
which occurs following the targeting of PP2A to the mitochondria and direct 
interaction with Bcl-2 via the PR61α/B’ subunit, and also by PP2A-mediated 
dephosphorylation and activation of the pro- apoptotic factor Bad. Another PP2A 
substrate involved in pro-survival signals is Rel A, an NF-κB transcription factor, 
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which has been found physically associated with the PR65/A subunit and whose 
transactivating activity is diminished upon direct dephosphorylation by PP2A (24). 
It has also been demonstrated that PP2A can negatively regulate the PI3K/Akt 
pathway by associating to and directly dephosphorylating Akt (25). Furthermore 
PP2A has a role downstream of Akt, specifically inhibiting the mTOR pathway; in 
fact PP2A directly inactivates S6 kinase, which is responsible for promoting cell 
growth by enhancing the translation of 5′TOP (containing a short polypyrimidine 
stretch at the 5′ terminus) mRNAs (26-28). PP2A also has an essential role in the 
regulation of Wnt signaling, a pathway linked to embryonic development, cell 
growth and stem cell self-renewal. In fact, a PP2A complex containing the B56γ 
subunit has been shown to be part of the β-catenin degradation complex, together 
with GSK3β and Axin where the PP2A catalytic subunit is involved in the process 
of inactivation and degradation of β-catenin, therefore shutting down the Wnt 
pathway (29). It becomes obvious that with such a diversity of functions, PP2A 
phosphatase activity needs to be tightly regulated. The primary level of regulation, 
as mentioned above, is the hetero-oligomeric composition of the PP2A complexes; 
however, PP2A can also undergo post-translational modifications and can be 
controlled by its association with inhibitory proteins. Until recently, the regulation of 
the quaternary structure of PP2A was poorly understood. However, the recent 
elucidation of the crystal structure of PP2A (30) led to the definition of a major role 
for the highly conserved C-terminal sequence of the C subunit (12, 31). It was 
already known that a C-terminal tyrosine residue (Tyr307) on the PP2A catalytic 
subunit could be phosphorylated, and that this event induces inactivation of the 
enzyme itself. In addition, PP2Ac can also be inactivated by phosphorylation on 
other, as yet unspecified, threonine residues, and in both cases PP2A can 
reactivate itself by auto-dephosphorylation (12, 31). The C-terminus of PP2AC is 
also reversibly carboxymethylated on Leu309 by a specific carboxyl 
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methyltransferase (LCMT1). This post-translational event appears to not directly 
affect PP2A phosphatase activity, but it is thought to affect holoenzyme 
composition. This idea has been re-investigated recently, and it appears that each 
B subunit family requires different levels of carboxymethylation on the C subunit to 
allow for assembly into the trimeric complex (31). Some subunits, such as PR55/B, 
require PP2Ac to be methylated, and others, such as PR61/B’ and PR72/B’’, 
associate only when the catalytic subunit is not methylated (31). These latest 
findings give new insights into the complexity of regulation of PP2A activity. 
Another level of complexity in the regulation of PP2A is the occurrence of 
several endogenous PP2A inhibitors, called I1PP2A, I2PP2A and CIP2A (32, 33). 
The biological significance of I1PP2A is still for the most part unknown. However, 
recent work has suggested a role for this protein in mediating the abnormal 
phosphorylation of the tau protein seen in Alzheimer’s disease (34). The 
Cancerous Inhibitor of PP2A (CIP2A) enhances the stability of the c-Myc through a 
mechanism that inhibits PP2A activity toward Serine 62 of this proto-oncogene. At 
last, I2PP2A, better known as SET, is the most characterized endogenous inhibitor 
of PP2A. SET is phosphorylated on two serine residues, most likely by PKC, and 
exerts its potent PP2A inhibitory activity via its N-terminal sequence (12, 35). Most 
importantly, SET has been found fused to the nucleoporin 214 (NUP214, CAN) 
protein in a form of acute non-lymphocytic myeloid leukemia with t(6,9) (36), 
associated with the oncoprotein MLL (mixed lineage leukemia, also called ALL1, 
HRX) in acute myeloid leukemia (37).  
PP2A and cancer 
The ability of PP2A to negatively and positively regulate mitogenic and 
apoptotic signals, respectively, has raised the hypothesis that PP2A might be 
involved in cancer development and progression. However, given the complexity of 
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PP2A regulation and its involvement in a wide variety of cellular mechanisms, it 
has been difficult to unequivocally and formally define PP2A as a bona fide tumor 
suppressor. The first lines of evidence implicating PP2A in cell transformation 
came in the late 1980s and early 1990s and were based on two observations. 
Firstly, that okadaic acid, a naturally occurring toxin and potent tumor promoter, is 
an inhibitor of PP2A (38). Secondly, that the SV40 small-t antigen interacts with 
PP2A/A and inhibits PP2A phosphatase activity by displacing several B subunits 
and that such inhibition is required for its function in cell transformation (39). 
However, it is only recently that inhibition of PP2A has become more widely 
accepted as being an essential step which allows cells to undergo complete 
transformation in response to activated oncogenes (11, 33, 40). Different PP2A 
subunits have now been found either mutated or aberrantly expressed in a number 
of malignancies that show loss of PP2A activity in conjunction with increased 
stability/activation of protein kinases and/or of their downstream targets (i.e. MAPK 
and Akt). 
The B subunit B56γ (of the PR61/B′ family) has been found overexpressed 
in metastatic melanoma cells compared to normal melanocytes (41); in these cells, 
PP2A failed to dephosphorylate the protein paxillin in focal adhesions, therefore 
enhancing the invasiveness of metastatic clones (42). Conversely, overexpression 
of B56γpartially reversed the tumorigenic activity of SV40-transformed cells and 
lung cancer cells (43). Accordingly, a truncated isoform of B56γ leading contributes 
to an enhanced metastatic potential of melanoma cells (44). This is in line with the 
notion that the major signaling pathways whose alterations are classically 
considered to trigger malignant transformation are regulated by the PP2A B56γ 
subunit. In fact, B56γ has been described as the regulatory subunit that targets 
PP2A to the Wnt/β-catenin and the MAPK signaling pathways and that elicits 
caspase-dependent apoptosis (29, 45, 46). 
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Although it seems that the PP2A:B56 form of the holoenzyme might 
represent a major player in cell transformation, the scaffolding PR65/A subunit has 
now been described as a tumor suppressor per se. Somatic mutations of both the 
α and β isoforms of PR65/A have been reported with high frequency in cancer. 
Interestingly, the Aβ isoform (PPP2R1B) gene has been found mutated in 15% of 
primary lung tumors, in 15% of colorectal carcinomas and in 13% of breast cancers 
(47-51). Moreover Aβ maps to chromosome 11q23, a region frequently deleted in 
various cancers and leukemias (52), and its loss-of-function cooperates with the 
expression of the large-T antigen, hTERT and H-RAS to transform human cells 
(40). Importantly, reintroduction of a wild-type Aβ partially reverses the tumorigenic 
phenotype of lung cancer cell lines (40). In this regard, a recent study (40) 
provided new insight into the role of PP2A/Aβ in cell transformation: PP2A/Aβ 
interacts with and modulates the activity of the small GTPase RalA, a known 
regulator of membrane transport, apoptosis, transcription, cell migration and cell 
proliferation (53). Sablina et al. (40) found RalA hyper-phosphorylated in cells 
lacking PP2A/Aβ expression and that regulation of RalA phosphorylation seems to 
be essential for the transformation associated with loss of PP2A/Aβ in cancer. In 
addition, the role of PP2A/Aβ as a tumor suppressor may likely be functionally 
explained by the disruption of the quaternary structure of PP2A complexes as 
consequence of the defective binding to B and/or C subunits and, therefore, 
resulting in impaired PP2A phosphatase activity towards specific substrates (48, 
54). Supporting the importance of PP2A A subunit in tumor formation and, perhaps 
in metastatic progression, there is also evidence that mutation of the 
PP2A/Aα subunit impaired phosphatase activity, led to activation of the Akt-
dependent survival signals and permitted cells to form tumors in mice, suggesting 
that cancer-associated mutations of PP2A/Aα contribute to cancer development by 
altering PP2A holoenzyme composition and function (55). 
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Inhibition of PP2A activity and, therefore, loss of its tumor suppressing 
potential, occurs at different levels, either within the structure of the multimeric 
enzyme itself (e.g. loss of expression/activity of one or more subunits), or through 
the activity of external effectors, whether endogenous (e.g. SET) or exogenous 
(e.g. okadaic acid, small-t antigen). For example, loss of Pml (promyelocytic 
leukemia gene) leads to tumorigenesis in the prostate through a mechanism that 
requires the recruitment of PP2A and phospho-Akt by Pml into the Pml nuclear 
bodies (56). Interestingly, Pml-null cells show suppression of PP2A phosphatase 
activity towards Akt that accumulates as nuclear phospho-Akt. As a consequence, 
the progressive reduction in Pml levels leads to inactivation of Foxo3a-mediated 
transcription of the proapoptotic protein Bim and the cell cycle inhibitor p27 (kip1) 
thus favoring cancer development (56). Likewise, a recently published report (33) 
identified a new endogenous inhibitor of PP2A, CIP2A (cancerous inhibitor of 
PP2A). This 90 kDa protein had already been found overexpressed in gastric 
cancers, but its function has remained elusive until recently (57). Junttila et al. (33) 
reported that siRNA-mediated downregulation of CIP2A in HeLa cells affected the 
expression of a variety known targets of c-Myc. Notably, the proto-oncogene c-Myc 
is a target of PP2A phosphatase activity (58-60), and the phosphorylation on 
Ser62 stabilizes this transcription factor and prevents its degradation (61). CIP2A 
strongly inhibits the phosphatase activity of PP2Ac, selectively targeting c-Myc-
associated PP2A complexes to prevent Ser62 dephosphorylation and 
consequently allow sustained and unrestrained c-Myc activity (33). These data 
suggest that CIP2A inhibition may be a possible strategy to induce targeted 
degradation of c-Myc in cancer cells. 
Recent studies, including from our group, have reported that the loss of 
PP2A phosphatase activity and, therefore its tumor suppressor ability, may play a 
central role in the development of different leukemias, such as Philadelphia-
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chromosome positive leukemias like CML and Ph(+) B-ALL, and also B-cell 
chronic lymphocytic leukemia (B-CLL) (62-64). B-CLL is the most common 
leukemia in adults, and deletion of the chromosome region 11q22–q23 is the 
second most common genomic alteration in B-CLL, representing a cohort of 
patients characterized by an adverse prognosis (65); interestingly, this region 
harbors the PP2A/Aβ locus. In their 2007 study, Kalla et al. (64) screened the 
remaining copy of the PP2A/Aβ gene for mutations in a number of patients carrying 
monoallelic deletion of this chromosome region. No deleterious mutations were 
found, confirming a previous report (66). However, the basal transcription of the 
PP2A/Aβ gene was found to be significantly lower in patients independent of the 
11q deletion. Moreover, they found three splicing variants of this PP2A subunit, 
characterized by skipping of exon 9, exon 3 or exons 2 and 3, and all were 
expected to interfere with the correct assembly of functional trimeric holoenzymes 
with consequent loss of domains necessary for interaction with C and B subunits 
(64). In agreement with the idea that disruption of the quaternary structure of PP2A 
most likely affects phosphatase activity, a significant reduction of PP2A activity 
was found in almost all of these B-CLL patients assayed, regardless of differences 
in the expression of the various PP2A/Aβ isoforms (64). As expected, an even 
greater reduction in PP2A phosphatase activity was observed in those patients 
expressing these splice variants. The potential role that PP2A may play in B-CLL 
was also investigated in a recent report by Liu et al. (67), in which the possibility of 
inducing PP2A activation as a possible therapeutic strategy for CLL was 
investigated in detail. The PP2A activator tested, FTY720 (Fingolimod; Novartis), is 
a known immunomodulator that is currently being evaluated in phase III clinical 
trials for multiple sclerosis (68, 69). FTY720 is a synthetic water-soluble myriocin 
analog that is structurally similar to sphingosine. It is a relatively non-toxic drug 
with high oral bioavailability and it reversibly arrests lymphocyte trafficking (70, 71). 
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FTY720 treatment of transformed B-cells induces apoptosis by a Bcl-2 
independent mechanism, and it also reduces phospho-ERK1/2 levels (67). More 
importantly, FTY720 treatment prolonged animal survival in a xenograft SCID 
mouse model of B cell lymphoma/leukemia (67). 
Chronic Myeloid Leukemia 
Chronic Myeloid Leukemia is a clonal disorder of the pluripotent 
haematopoietic stem cells and is clinically characterized by two distinct stages, a 
protracted myeloproliferative disorder termed chronic phase (CML-CP) that 
progresses to a rapidly fatal blast crisis (CML-BC) (7). CML-CP, largely 
asymptomatic, is distinguished by the expansion and accumulation of terminally 
differentiated neutrophil granulocytes in the peripheral blood. If left untreated CML-
CP inevitably progresses to the blast phase, characterized by accumulation of 
blast cells in the peripheral blood that are unable to differentiate; CML-BC is the 
terminal phase of this malignancy and behaves as an acute leukemia (7).  CML 
has been the first cancer to be linked to a specific somatic genetic abnormality (7). 
In fact the main feature of CML is the presence of the Philadelphia chromosome 
(Ph1), product of the reciprocal translocation between chromosome 9 and 
chromosome 22, t(9;22)(q34;q11). The translocation results in the fusion of the 
BCR (9q22) to the c-ABL (22q11) gene. In CML, the BCR/ABL fusion gene 
encodes for a 210kDa protein called p210-BCR/ABL. Depending on the location of 
the breaking point on the BCR locus the product of the t(9;22) can also be a p190- 
or a p230-BCR/ABL, which are normally detected in Philadelphia-positive B-acute 
lymphoblastic leukemia (Ph1 ALL) and chronic neutrophilic leukemia (CNL) 
respectively (72).  
It has been well established that the sole expression of p210-BCR/ABL is 
necessary and sufficient for the induction of chronic phase CML (7). In blast crisis 
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CML other frequent genetic and molecular abnormalities arise (e.g. double Ph1 
chromosome, p53 inactivation) (73), but increased expression and activity of the 
BCR/ABL oncoprotein still appear to be playing a central role in the progression of 
the disease (74-76), in fact, sustained BCR/ABL expression in myeloid progenitor 
cell lines induces phenotypic changes (i.e. differentiation arrest) characteristic of 
CML-BC (77). Moreover high levels of BCR/ABL activity as seen in CML-BC trigger 
oxidative stress in the cells, which is likely responsible for the induction of DNA 
damage and secondary genetic abnormalities. The ability of BCR/ABL to induce 
and sustain the leukemic phenotype depends on its unrestrained tyrosine kinase 
activity (7). BCR/ABL constitutive kinase activity is essential for the recruitment and 
activation of multiple pathways that transduce oncogenic signals leading to growth 
factor-independent proliferation, increased survival and altered differentiation (78) 
of myeloid precursors. In fact, the effect of BCR/ABL transformation is mostly 
dependent on post-translational modifications (e.g. phosphorylation) of signaling 
molecules, like those involved in the RAS/MAPK, PI3K/Akt and STATs pathways, 
which control cell growth, survival and differentiation of haematopoietic cells by 
modulating the expression and/or activity of downstream effectors (79, 80) (Figure 
2). In blast crisis, increased expression of the BCR/ABL oncoprotein accounts for 
the block of differentiation, inactivation of factors with tumour suppressor activity 
and decreased genomic stability of the Ph1 blasts (7, 78, 81, 82). Thus, 
dependence on BCR/ABL expression is not only a characteristic of CML-CP but 
also of CML-BC; however, BCR/ABL-independent mechanisms also seem to 
contribute to disease progression and treatment resistance in some CML cases 
(83, 84). 
Since the deregulated BCR/ABL kinase activity is the recognized culprit of 
cause of CML, targeting its catalytic domain was the most rationale method for the 
development of small molecules that inhibit ABL kinase activity. Through a 
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combination of high-throughput screening and a structure-based drug design 
approach the Signal Transduction Inhibitor 571 (STI571) was developed in the late 
90s. Now commercialized as Imatinib Mesylate (Gleevec, Novartis Basel, 
Switzerland), it is a c-Kit, c-Abl and PDGFR inhibitor, and induces apoptosis of the 
Ph1 CML progenitors by suppressing the ability of BCR/ABL to phosphorylate 
substrates through competitive inhibition at the BCR/ABL ATP binding site (85). 
The development of the BCR/ABL tyrosine kinase inhibitor Imatinib Mesylate as 
the treatment of choice for chronic phase CML has changed the natural history of 
the disease with up to 90% of the patients achieving a complete cytogenetic 
response in chronic phase. Its remarkable therapeutic effects suggest that blast 
crisis transition will be postponed for several years in the majority of CML patients 
(86, 87). However, the persistence of BCR/ABL transcripts in a cohort of patients 
with complete cytogenetic response (88) and the resistance of the primitive CML 
stem cell to Imatinib treatment (89) raises the possibility that treatment with 
Imatinib alone might delay but not prevent disease progression. Furthermore, most 
of the CML patients that start the treatment in the accelerated and blastic phases 
of the disease are either refractory or develop resistance to Imatinib monotherapy 
(86). In these CML-BC patients, Imatinib resistance often depends on reactivation 
of BCR/ABL tyrosine kinase activity via mechanisms involving BCR/ABL 
overexpression, gene amplification or mutations that suppress Imatinib-mediated 
kinase inhibition (i.e. E255V and G250E) or disrupt Imatinib binding (i.e. T315I) 
(90). Thus, development of Imatinib resistance appears to predispose to blastic 
transformation. Hence, second generation tyrosine kinase inhibitors have been 
developed in the past few years. Although new clinical trials with the dual Src/Abl 
inhibitor Dasatinib (BMS-354825) and the selective Abl inhibitor Nilotinib 
(AMN1070) show encouraging results (91), as they suppress the activity of most 
BCR/ABL mutants (except T315I) (91), in vitro evidence suggests that resistance 
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Figure 2. Top: Schematic representation of some of the pathways activated by p210BCR/ABL and involved in the BCR/ABL-
dependent induction of the transformed phenotype in CML. Bottom: Schematic representation of the BCR/ABL-induced and 
RNA binding protein-mediated pathways affecting proliferation survival and differentiation of CML-BC progenitors.  
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to these new compounds may develop through mechanisms involving the selection 
and expansion of BCR/ABL cell clones carrying the T315I BCR/ABL mutant (92). 
Additionally, Dasatinib and Nilotinib, like Imatinib, are not effective in the treatment 
of CML-BC patients (93).  
The mechanisms responsible for transition of CML chronic phase into blast 
crisis remain poorly understood, although a reasonable assumption is that the 
unrestrained activity of BCR/ ABL in hematopoietic stem/progenitor cells is the 
primary determinant of disease progression. However, a plausible model of 
disease progression predicts that increased BCR/ABL expression promotes the 
secondary molecular and chromosomal changes essential for the expansion of cell 
clones with increasingly malignant characteristics, and remains crucial for the 
transformed phenotype even in advanced stages of the disease (7). According to 
this model, CML blast crisis would be expected to occur only in patients with an 
imatinib-resistant disease or in those developing resistance during treatment. 
Indeed, a recent study from the GIMEMA Working Party on CML reported that the 
early detection of BCR/ABL mutations in CML chronic phase patients is associated 
with a greater likelihood of disease progression (94). Interestingly, a direct 
correlation also seems to exist between levels of BCR/ABL activity and 
development of imatinib resistance (95, 96).  
Another level of complexity in the treatment of CML is the fact that there is 
increasing evidence that the most primitive and quiescent CML stem cells, 
designated as leukemic stem cells or cancer initiating cells, appear to be 
intrinsically insensitive to the tyrosine kinase inhibitors(89, 97). Therefore, therapy 
with Imatinib may never be curative and indefinite treatment may be required for a 
sustained response; this may pose the risk of developing resistance or intolerance 
leaving the opportunity open for a possible relapse of CML given the persistence of 
a pool of leukemic stem cells. Interestingly the resistance of the quiescent stem 
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cells to BCR/ABL inhibition is raising the possibility that, paradoxically, the survival 
of LSCs may be to some degree, if not completely, independent of BCR/ABL.  
Aim of This Study  
The natural history of CML has been radically changed by the introduction 
of Imatinib and second-generation tyrosine kinase inhibitors (Dasatinib and 
Nilotinib), but relapse and progression into the blast phase of the disease, as a 
consequence of arising of BCR/ABL mutations and/or intolerance to the treatment, 
is a possibility that still exists and cannot be ignored. Moreover patients that may 
be diagnosed during the blast crisis do not have any feasible therapeutic option 
and to this day the only curative regimen for CML is bone marrow transplantation. 
Therefore, there is still a need for new drugs that, if used in combination with the 
available kinase inhibitors, may help decrease the rate of relapse, prevent blastic 
transformation and, perhaps, overcome Imatinib resistance. Therefore, a better 
understanding of the biology of CML-BC is necessary to identify molecular 
networks that, if appropriately modulated, will simultaneously affect the function of 
BCR/ABL and that of multiple signals aberrantly activated in CML-BC. Moreover, in 
light of the recent findings concerning the insensitivity of the leukemic stem cells to 
the tyrosine kinase inhibitors (97), many groups, including ours, are now poised to 
dissect the biology of the leukemic stem cells and to find alternative factors in 
charge of the survival and self-renewal of the cancer initiating cells, and that could 
be targeted in the hope of eradicating CML at a stem cell level, which could 
eventually result into a long-term cure. Therefore the main objective of these 
studies is to dissect the mechanisms responsible for disease progression in CML. 
In BCR/ABL-expressing myeloid progenitor cell lines, high levels of 
BCR/ABL, as those observed in CML-BC, suppress differentiation, enhance 
survival and increase resistance to drug-induced apoptosis in part by enhancing 
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the expression and activity of specific RNA binding proteins (78, 82, 98, 99) (Figure 
2). Such an increase in the expression of these mRNA-binding proteins correlates 
with the levels of BCR/ABL and is sensitive to the treatment with Imatinib (77, 82, 
98, 100). In BCR/ABL-expressing hematopoietic cells, expression of these RNA-
binding proteins results from enhanced gene transcription (eg hnRNP A2/B1, 
hnRNP K, JKTBP1, hnRNP D1, Tra2b, RNPS1, EWSh, SC-35, Pabp2 and hnRNP 
H1), or increased protein stability (ie TLS/FUS, hnRNP A1, hnRNP E2 and La/ 
SSB) (77, 78, 82, 99-101). In this study, we focused on the nucleocytoplasmic 
shuttling protein hnRNP A1, a previously described protein required for BCR/ABL 
leukemogenesis (100), and we identified SET (I2PP2A), a phosphoprotein already 
described as being overexpressed in solid tumors and leukemias (102, 103), as a 
novel target of BCR/ABL whose mRNA transport, from the nucleus to the 
translation machinery in the cytoplasm, is dependent on hnRNP A1(62). SET is a 
potent inhibitor of the tumor suppressor PP2A (35). This preliminary finding raised 
the possibility that PP2A could be involved in the leukemogenesis of CML, and that 
its inhibition, through SET, may be a mechanism that is put in place by BCR/ABL 
to suppress PP2A tumor suppressive ability and to allow for the progression of the 
disease. 
 
MATERIAL AND METHODS 
Cell cultures and primary cells 
The Ph1 K562, the BCR/ABL-expressing 32Dcl3 and BaF3 cells, and their 
derivative lines were maintained in culture in IMDM/10% FBS/2 mM L-glutamine. 
The 32D-p210BCR/ABL, 32D-p210BCR/ABL (T315I), BaF3-p190BCR/ABL, 32D-
BCR/ABL-pBABE-GFP, and 32D-BCR/ABL-GFP–small-t cells were generated by 
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retroviral infection followed by FACS-mediated sorting of the GFP-positive fraction 
(green fluorescent protein) or by antibiotic-mediated selection (78). Frozen 
samples of CD34+ NBM cells from different healthy donors were purchased from 
Cincinnati Children’s Hospital. Frozen samples of mononuclear hematopoietic cells 
from bone marrow or peripheral blood of unidentifiable CML and Ph1 ALL patients 
were Ficoll separated and used to isolate the CD34+ and/or CD19+ fraction by 
using the CD34 MultiSort kit and/or CD19 microbeads (Miltenyi Biotec). The same 
method was used to isolate the CD19+ fraction from the normal CD34+ marrow 
progenitors. Before being used in different assays, CD34+ and CD34+/CD19+ 
progenitors from healthy donors and leukemic patients were kept overnight in 
IMDM supplemented with 30% FBS, 2 mM glutamine, and human recombinant 
cytokines. Specifically, NBMCD34+, CML-CPCD34+ and CML-BCCD34+ cells were kept 
in IL-3 (20 ng/ml), IL-6 (20 ng/ml), Flt-3 ligand (100 ng/ml), and KL (100 ng/ml) 
(Stem Cell Technologies Inc.), whereas NBMCD34+/CD19+ and Ph1 ALLCD34+/CD19+ 
cells were cultured in IL-7 (100 ng/ml) (Peprotech Inc.), SCF, and Flt-3 ligand, 
respectively. All studies were performed with human specimens obtained from The 
Ohio State University Leukemia Tissue Bank; the Division of Hematology, 
Maisonneuve-Rosemont Hospital (Montreal, Canada), Division of Experimental 
Oncology, National Cancer Institute (Milan, Italy), and from the Department 
Hematology and Oncology, Oregon Health and Science University and were done 
with approval from The Ohio State University Institutional Review Board. Ph1 ALL 
patient samples were obtained from the Cancer and Leukemia Group B Leukemia 
Tissue Bank at The Ohio State University. The percentage of CML-CP Ph+ cells 
analyzed by FISH ranged from 91% to 100%. The CML-BC samples were all 
myeloid BC and mostly with complex karyotype, and no CML-BC samples had 
deletions of the der9q. Likewise, the Ph1 ALL bone marrow samples at diagnosis 
showed high blast counts and were mostly p190 BCR/ABL+ (2 of 12 expressed a 
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p210 BCR/ABL oncoprotein). Where indicated, cells were treated with the 
following: ALLN, okadaic acid, , sodium stibogluconate, and butyryl-forkolin (EMD 
Bioscience Inc.); forskolin, 1,9-dideoxy-forskolin (BioMol); Imatinib (Novartis); 
Dasatinib (Bristol-Myers Squibb). FTY720 was synthesized with subsequent HPLC 
purification as described in (104). The identity and purity were confirmed by 
nuclear magnetic resonance and mass spectrometry. 
Plasmids 
pHM6-HA-PP2Ac contains the HA-tagged PP2A catalytic subunit under the 
control of the CMV promoter (P.B. Rothman, Columbia University, New York, NY).  
MigRI-HA-PP2Ac. The HA-tagged PP2Ac cDNA was PCR amplified from 
pHM6-HA-PP2Ac and subcloned into the HpaI/EcoRI sites of the bicistronic GFP-
containing MigRI vector.  
pSuper.retro-shSET. The shRNA SET construct was obtained by subcloning 
the double-stranded 60 mer oligonucleotide containing the SET target sequence 
(5’-TGAAATAGACAGACTTAAT-3’) into the pSuper.retro.neo+GFP vector 
(OligoEngine). 
MSCV-FLAG-SET. The human SET cDNA was obtained from K562 mRNA 
by RT-PCR using an upstream primer containing a HpaI site, the FLAG epitope, 
and the first 16 nucleotides of SET cDNA, and a downstream primer containing the 
last 21 nucleotides of SET linked to an EcoRI restriction site. The HpaI/EcoRI-
digested PCR product was subcloned into the MSCV-puro vector. 
pBABE-GFP-sTAg. The retroviral vector pBABE-GFP and its derivative 
pBABE-GFP-sTAg carrying the SV40 small-t (Addgene plasmid 10673; provided 
by William C. Hahn, Dana-Farber Cancer Institute, Boston, Massachusetts, USA) 
have been described elsewhere (75). 
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RT‐PCR of immunoprecipitated RNA (Ribonomics) 
K562 cells (108) were lysed in 2 pellet/vol of 10 mM HEPES (pH 7.0), 100 
mM KCl, 1 mM MgCl2, 1 mM DTT, 0.5% Nonidet P-40, 100 U/ml RNase OUT 
(Invitrogen), 0.2 mM PMSF, 1 mg/ml pepstatin A, 5 mg/ml bestatin, and 20 mg/ml 
leupeptin, and clarified (100,000 × g, 2.5 hr). RNP-containing particles were 
purified by centrifugation (300,000 × g; 3 hr) and resuspended in 1 ml of 50 mM 
Tris (pH 7.4), 150 mM NaCl, 1 mM MgCl2, 0.05% NP-40, 100 U/ml RNase OUT, 
0.2 mM PMSF, and 20 mM EDTA. Immunoprecipitation (IP) and extraction of the 
hnRNP A1 bound mRNA was performed as described (105). The presence of SET 
transcripts was assessed by RT-PCR performed on an equal amount of RNA, 
extracted from RNP-enriched lysates (input) as well as from the hnRNP-A1 or 
FLAG immunoprecipitates. To amplify SET mRNA, the following primers were 
used:  
5’-GAGGTCAGAATTGATCGCCAAAATC-3’  
5’-TCAGATGAAATTCTTTGGAGAGAAC-3’ 
Nested RT‐PCR 
To detect BCR/ABL transcripts, RNA was extracted (QIAamp RNA blood kit; 
Qiagen) from mouse peripheral blood. RNA from K562:32Dcl3 cells (ratio 1:106) 
served as positive control, whereas RNA from blood of mice that were not injected 
with BCR/ABL+ cells was used as negative control. Total RNA was reverse 
transcribed and cDNA was used to detect BCR/ABL transcripts by nested PCR 
using a first set of primers spanning the bcr exon 1/abl exon 3 and a second set 
amplifying a bcr exon 2/abl exon 3 fragment. The nested RT-PCR conditions were 
previously described (106). GAPDH levels were monitored as control for equal 
amplification. 
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Western blot analysis  
Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 50 
mM Tris [pH 8.0]) supplemented with protease and phosphatase inhibitors. After 
incubation on ice, lysates were clarified (12,000 × g, 15 min, 4°C), denatured, and 
subjected to SDS-PAGE and Western blot (100). The antibodies used were goat 
polyclonal anti-SET (I2PP2A) (Santa Cruz Biotechnology); monoclonal anti-Abl 
(Ab-3), (EMD); monoclonal anti-phosphotyrosine 4G10 monoclonal anti-PP2Ac, 
clone 1D6 (Upstate Inc.); monoclonal anti-hnRNP A1 (9H10) (G. Dreyfuss, 
University of Pennsylvania, Philadelphia, PA); monoclonal anti-GRB2 (BD 
Biosciences). 
Analysis of apoptosis and caspase activation 
Apoptosis was measured using the Annexin V–FITC apoptosis detection kit 
(BD Biosciences) according to the manufacturer’s instructions. Briefly, FTY720-
treated and untreated cells were Annexin V-FITC- and propidium iodide-stained for 
15 minutes in binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM 
CaCl2) and analyzed by flow cytometry using a FACSCalibur (BD Biosciences). 
Likewise, caspase-3/7 activities were measured on untreated and FTY720-treated 
cells using the caspase Glo-3/7 assay kit (Promega Corp.). Briefly, 5×103 cells 
were plated in a white-walled 96-well plate, and the Z-DEVD reagent, a 
luminogenic caspase 3/7 substrate, which contains the tetrapeptide Asp-Glu-Val-
Asp, was added with a 1:1 ratio of reagent to cell solution. After 90 minutes at 
room temperature, the substrate cleavage by activated caspase-3 and -7, and the 
intensity of a luminescent signal was measured by a Fluoroskan Ascent FL 
luminometer (Thermo Electron Corp.). Differences in caspase-3/7 activity in 
FTY720-treated cells compared with untreated cells are expressed as fold-change 
in luminescence. 
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Phosphatase assays 
PP2A phosphatase assays were carried out using the PP2A IP 
phosphatase assay kit (Upstate). Briefly, protein lysates in 100μl of 20 mM HEPES 
(pH 7.0), 100 mM NaCl, 5 μg of PP2Ac antibody (Upstate), and 25 μl of Protein A-
agarose were added to 400 μl of 50 mM Tris (pH 7.0)/100 mM CaCl2, and IPs were 
carried out at 4°C for 2 hr. IPs were washed and used in the phosphatase reaction 
according to the manufacturer’s protocol. 
Clonogenic assays 
Clonogenic assays were performed by plating 5×104 cells from primary 
human NBM, CML, and Ph1 ALL progenitors in 0.9% MethoCult H4230 (StemCell 
Technologies Inc.). CML and NBMCD34+ cells were plated in the presence of 
recombinant human IL-3 (100 ng/ml); Ph1 ALL and NBMCD34+/CD19+ cells were 
plated in the presence of recombinant human IL-7 (100 ng/ml). Colonies (>125 μm) 
were scored 15 days later. 
Leukemogenesis in SCID mice 
Four- to six-week-old ICR-SCID mice were intra-venously injected with 
5×105 32D-p210BCR/ABL, 32D-p210BCR/ABL (T315I), or BaF3p190BCR/ABL cells (26 
mice/group). After engraftment (presence of BCR/ABL+ cells in peripheral blood 7 
days after cell injection), cell-injected mice (13 mice/group) were intra-peritoneally 
treated with 10 mg/kg/day of FTY720 in saline solution. Age-matched mice or mice 
injected with cells or drugs only (13 mice) served as controls. Four weeks after 
injection, 3 mice from each group were sacrificed and organs were analyzed for 
the presence of leukemia. The disease process was monitored by nested RT-PCR-
mediated detection of p210 or p190 BCR/ABL transcripts using peripheral blood 
collected by lateral tail-vein incision. The remaining mice were used for survival 
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studies that were terminated 24 or 27 weeks after injection. For pathological 
examination, tissue sections from bone marrow, spleen, liver, kidney, heart, lung, 
and brain were fixed in formalin, embedded in paraffin, and H&E stained. 
Peripheral blood was collected by periorbital bleeding, depleted of red blood cells, 
cytospun onto a glass slide, and May-Grunwald/Giemsa stained.  
Intracellular flow cytometry 
CML-BCCD34+ and NBMCD34+ primary cells were stained with the following 
fluorochrome-conjugated monoclonal antibody directed to surface markers: anti-
human CD34-FITC and CD45Rα-PE (BD Biosciences) and CD38-Alexa Fluor 700 
(eBioscience). Cells were then fixed and permeabilized using the BD 
Cytofix/Cytoperm solution kit (BD Biosciences) according to manufacturer 
instructions. The permeabilized cells were then stained with one of the following 
unconjugated primary antibodies: rabbit monoclonal anti-I2PP2A (SET, 
GloboZymes), rabbit polyclonal anti-phospho-Crkl or rabbit polyclonal anti-
phospho-Abl (Cell signaling Technology). The detection of the intracellular marker 
was done by indirect staining with a secondary anti-rabbit f(ab)’ antibody fragment 
conjugated to Aleza Fluor 647 (Invitrogen). Samples were analyzed by acquisition 
on an LSRII flow cytometert (BD Biosciences). 
Long‐term culture initiating‐cell assays 
2x106 bone marrow cells from CML-BC were cultured with irradiated M2-
10B4 fibroblasts in MyeloCult H5100 medium (StemCell Technologies) 
supplemented with hydrocortisone according to the manufacturer’s instructions. In 
the first week, the indicated drugs were added to the culture. The medium 
containing the compounds was then replaced after 7 days, and half of the medium 
was replaced every 7 days in the following weeks. After 5 weeks of culture, 
adherent and non-adherent cells were harvested and 5x104 cells were plated into 
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MethoCult medium containing recombinant human SCF, recombinant human GM-
CSF, recombinant human IL-3, recombinant human IL-6, recombinant human G-
CSF, recombinant human Erythropoietin (StemCell Technologies H4435). 
Numbers of colonies derived from long-term culture-initiating cells (LTC-ICs) were 
counted after 20 days. 
CFSE Assay 
CML-BCCD34+ and NBMCD34+ cells were stained with CarboxyFluorescein 
Succinimidyl Ester from the CellTrace CFSE Cell proliferation kit according to 
manufacture instruction (Invitrogen). A narrow gate of CFSE+ cells was then 
sorted with a FACS-AriaII (BD Biosciences) in order to allow for resolution of the 
peaks corresponding to the cell divisions. After nine days in culture in the presence 
of the indicated drugs the cells were harvested and stained with propidium iodide 
(PI, in order to exclude dead cells and debris from the analysis), Annexin-V V450 
(BD Biosciences) and anti-CD34-Alexa Fluor 647 (eBioscience). The percentage of 
CFSEmax/CD34+ at nine days cells was representative of the number of cells that 
never underwent any division over the time in culture. Where indicated the CFSE-
stained cells were utilized for the intracellular staining of phospho-Abl, as 
described above. 
RESULTS 
SET/hnRNP A1/PP2A interplay 
Using Ribonomics (105), SET mRNA was found specifically associated with 
cytoplasmic hnRNP A1 in the Philadelphia translocation positive K562 human cell 
line. To validate the SET mRNA-hnRNP A1 association, human SET-specific RT-
PCR was carried out on anti-hnRNP A1- and anti-FLAG (unrelated antibody)-
immunoprecipitated cytoplasmic mRNAs. High levels of SET mRNA transcripts, 
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similar to those present in the mRNP-enriched mRNA fraction, were clearly 
detectable in association with hnRNP A1 (Figure 3A). This suggested that the 
regulation of SET expression may be dependent on the nucleo-cytoplasmic 
shuttling of its mRNA bound to hnRNP A1 and, as a consequence, dependent 
BCR/ABL expression/activity. In fact, SET expression was higher in myeloid CML-
BC than in CML-CP patient derived mononuclear marrow cells (Figure 3B); 
moreover SET protein levels correlated with levels of BCR/ABL, and were higher in 
myeloid CML-BCCD34+ than CMLCPCD34+ patient-derived bone marrow progenitor 
cells, and in CML-CPCD34+ patient cells than in CD34+ primary cells from healthy 
donors (NBM) (Figure 3C). Furthermore, treatment of CML-BCCD34+ cells with 
Imatinib decreased SET and, as expected, hnRNP A1 levels (Figure 3D) further 
indicating that BCR/ABL activity is responsible for SET upregulation in CML-BC. In 
the BCR/ABL-transformed myeloid cell line 32Dcl3 (32D-BCR/ABL) and in CML-
BCCD34+ patient cells (Figure 4A) total expression of PP2A was not affected by 
BCR/ABL expression and/or kinase activity (post-Imatinib treatment). By contrast, 
PP2A activity, was reduced by 94% and 52% in the CD34+ fraction of myeloid 
CML-BC and CML-CP cells, respectively, compared to the CD34+ fraction of NBM 
cells (Figure 4B), consistent with the notion that SET is an endogenous inhibitor of 
PP2A phosphatase activity. To determine whether SET upregulation is responsible 
Figure 3. A: RT-PCR shows association of SET mRNA with hnRNP A1 in mRNP-enriched lysates, anti-FLAG-IP (negative 
control), and anti-hnRNP A1-IP from K562 cells. B: scatter plots show SET protein levels in BM cells from seven CML-CP and -
BC patient specimens (p = 0.003; Wilcoxon rank sum test). C: graph shows SET (light bars) and BCR/ABL (dark bars) protein 
expression (expressed as mean ± SE of densitometric units after normalization with Grb2 levels) in the CD34+ fraction from 
bone marrow of healthy donors (NBM) (n = 3), CML-CP (n = 3), and CML-BC (n = 3) patients (NBM versus CML-CP, p = 0.03; 
CML-CP versus CML-BC, p = 0.004; paired samples t test). D: SET, hnRNP A1, and BCR/ABL protein levels in untreated and 
imatinib-treated CML-BCCD34+ cells. 
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for suppression of PP2A activity, we interfered with SET expression by transducing 
32D-BCR/ABL cells with a pSuper.retro-shSET construct carrying a short hairpin 
RNA (shRNA) targeting SET mRNA (Figure 4C). Expression of SET shRNA 
downregulated levels of SET and restored PP2A activity to levels similar to those 
of 32Dcl3 or imatinib-treated 32D-BCR/ABL cells (Figure 4B), without affecting 
PP2Ac expression (Figure 4A). 
 
 
 
Relevance of PP2A activity suppression in CML 
The suppression of the phosphatase activity of PP2A appears to be 
required by BCR/ABL to keep its tyrosine kinase in an active status, in fact 
Figure 4. A: protein levels of PP2Ac and Grb2 in the following: 32Dcl3, untreated and imatinib-treated 32D-BCR/ABL and 
primary CML-BCCD34+ marrow cells, and SET shRNA-expressing 32D-BCR/ABL. B: effect of the SET shRNA on SET 
levels C and D: PP2A phosphatase assay in 32Dcl3, 32D-BCR/ABL, CML-BCCD34+, CML-CPCD34+, and 
NBMCD34+cells, and in BCR/ABL cells expressing the SET shRNA or HA-PP2Ac or treated with imatinib. Bars represent 
the PP2A activity (expressed as mean ± SE of three independent experiments performed with the indicated cell lines, and 
with NBMCD34+ (n = 3), CML-CPCD34+ (n = 3), and CML-BCCD34+ (n = 3) cells. 
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BCR/ABL itself is a target of PP2A. Expression of SET shRNA or HA-PP2A in 32D-
BCR/ABL cells suppressed p210BCR/ABL tyrosine phosphorylation and expression 
(Figure 5A). This effect, was dependent on enhanced PP2A phosphatase activity 
because both SET overexpression and treatment with the phosphatase inhibitor 
okadaic acid used at concentrations that inhibit PP2A but not other phosphatases 
(107), restored BCR/ABL activity and expression in HA-PP2Ac-transduced cells 
(Figure 5A). Conversely, exposure of Imatinib-sensitive and -resistant (T315I) 
BCR/ABL+ cell lines and CML-BCCD34+ marrow blasts to the PP2A activators (108) 
forskolin (40μM), butyryl-forskolin (water soluble), or 1,9-dideoxy-forskolin (lacks 
adenylate cyclase-activating function) enhanced PP2A activity abolished BCR/ABL 
phosphorylation, and induced downregulation of BCR/ABL (Figure 5B). To 
determine whether PP2A-induced BCR/ABL dephosphorylation renders BCR/ABL 
more susceptible to proteolysis, we treated PP2A-expressing 32D-BCR/ABL cells 
with the proteasome inhibitor ALLN. As shown, ALLN restored BCR/ABL 
expression and, as expected, did not prevent PP2A-induced BCR/ABL tyrosine 
dephosphorylation (Figure 5C), which precedes and, likely, is required for its 
degradation. Interestingly, tyrosine dephosphorylation of BCR/ABL appeared to be 
dependent on the activity of another phosphatase, SHP-1, that had already been 
described as relevant in BCR/ABL expressing cells (109). In fact restored 
BCR/ABL phosphorylation was observed after treatment of SET shRNA- and HA-
PP2A-expressing 32D-BCR/ABL cells with sodium stibogluconate (SS) (Figure 
5D), a specific SHP-1 inhibitor (110). According to these observation it seemed 
plausible that PP2A inactivation by BCR/ABL in a kinase and dosage dependent 
manner may be an important step in the progression of CML to the blast phase 
and that inactivation of the tumor suppressor PP2A may be a necessary event 
required to keep BCR/ABL kinase activity unrestrained both in chronic phase and, 
to a greater extent, in blast crisis where BCR/ABL activity is at its highest and 
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PP2A activity, as a consequence, is at its lowest.  In this scenario PP2A 
phosphatase activity induction could be envisioned as a new therapeutic strategy 
to be used in parallel with tyrosine kinase inhibitors to enhance BCR/ABL 
inhibition.  
Pre‐clinical evaluation of the PP2A activator FTY720. 
In light of the discovery of the role of PP2A in CML we have assessed the 
therapeutic potential of the PP2A activator FTY720 (111) (also known as 
Fingolimod, Novartis) in CML-BC and Philadelphia-positive Acute Lymphoblastic 
Leukemia (Ph1 ALL, expressing the isoform p190 of the BCR/ABL oncoproteins) 
on progenitors and in models of in vitro and in vivo p210 and p190 BCR/ABL 
Figure 5. A: p210BCR/ABL activity (αPY) and expression (α-Abl) in 32D-BCR/ABL and in its derivative SET shRNA-, HA-
PP2A-, and HA-PP2A/FLAG-SET-expressing cell lines, and in HA-PP2A 32D-BCR/ABL cells treated with okadaic acid. B: 
Effect of the PP2A activators forskolin, butyryl-forskolin, and 1,9-dideoxy- forskolin on BCR/ABL activity and expression in 
primary CML-BC and ima- tinib-sensitive and -resistant BCR/ABL cell lines. C: p210BCR/ABL activity and expression in 
parental and untreated or ALLN-treated HA-PP2A-expressing 32D-BCR/ABL cells. D: Effect of the SHP-1 inhibitor sodium 
stibogluconate (SS) on BCR/ABL activity in parental and HA-PP2A- and SET shRNA-expressing 32D-BCR/ABL cells. 
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leukemogenesis. FTY720, a synthetic myriocin analog structurally similar to 
sphingosine, is a water-soluble drug with high oral bioavailability that reversibly 
arrests lymphocyte trafficking (mainly of CD4+ T cells) (71, 112-114). It is currently 
used as an immunomodulator in Phase III trials for patients with multiple sclerosis. 
We have investigated and produced data that may support FTY720 as a novel 
therapeutic approach for patients with Imatinib/Dasatinib-sensitive and -resistant 
CML and also for Ph1-ALL.  
FTY720 restores the activity of PP2A and inhibits that of p210 and 
p190 BCR/ABL 
 
The dose/time-dependent effect of FTY720 on BCR/ABL-expression/activity was 
initially assessed in p210BCR/ABL-transformed myeloid precursor 32Dcl3 cells. 
Levels of tyrosine-phosphorylated (active) p210BCR/ABL were dramatically reduced 
within 6 hours, barely detectable at 12 hours, and absent at 24 hours of treatment 
with 2.5 ⎧M FTY720 (Figure 6). Similarly, BCR/ABL expression was downregulated 
by 2.5 ⎧M FTY720, although this occurred at later time points than 
dephosphorylation (Figure 6). BCR/ABL-transformed cells were also treated with 
escalating doses of FTY720 (concentrations of 0.01 to 2.5 ⎧M) (Figure 6). Indeed, 
FTY720 treatment at 36 hours suppressed BCR/ABL activity with a 50% effective 
Figure 6: p210BCR/ABL tyrosine phosphorylation (αPY) and expression (αAbl) in 32D-BCR/ABL cells untreated and treated 6–36 
hours with 2.5 μM FTY720 (left panel). Graph shows levels of phosphorylated BCR/ABL (expressed as arbitrary densitometric 
units normalized to Grb2 levels) in 32D-BCR/ABL cells treated for 36 hours with the indicated concentrations of FTY720. Right 
blot: p210BCR/ABL activity in 32D-p210BCR/ABL cells treated for 36 hours with FTY720. 
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concentration (EC50) of approximately 80 nM (Figure 6).  
As already demonstrated, PP2A activity was reduced by 90% in myeloid CML-
BCCD34+ compared to the CD34+ fraction from healthy bone marrow (NBM) donors, 
and also reduced by 82% in Ph1 ALLCD34+/CD19+ lymphoid blasts compared to the 
CD34+/CD19+ fraction from NBM donors (Figure 2A). Consistently, treatment of 
CML-BCCD34+ and Ph1 ALLCD34+/CD19+ progenitors with FTY720 in the presence of 
myeloid or lymphoid cytokines reestablished PP2A activity to levels observed in 
normal CD34+ myeloid and CD34+/CD19+ lymphoid progenitors (Figure 7A). By 
contrast, FTY720 did not over induce PP2A activity in primary NBM progenitors 
(Figure 7A).  
As in myeloid CML-BC (62), suppression of PP2A activity in Ph1 ALL is also 
dependent on enhanced expression of the BCR/ ABL-regulated SET (62). In fact, 
SET protein levels were significantly higher in Ph1 ALLCD34+/CD19+ than in Ph1 
NBMCD34+/CD19+progenitors (Figure 7A). Thus enhanced SET expression represents 
a common mechanism used by both p210 (62) and p190 BCR/ABL oncoproteins 
Figure 7. A: PP2A assay in untreated (black bars) and FTY720-treated (red bars) CML-BCCD34+ (n = 11), and Ph1 
ALLCD34+/CD19+ (n = 12); Dot plot shows SET protein levels expressed as arbitrary densitometric units normalized to Grb2 protein 
levels in NBMCD34+/CD19+ (n = 4) and Ph1 ALLCD34+/CD19+ cells (n = 12) (P < 0.001, Student t-test). B: Western blots 
show effect of small-t expression on BCR/ABL activity and expression in untreated and FTY720-treated 32D-p210BCR/ABL 
cells. C: p210BCR/ABL and p190BCR/ABL activity and expression in untreated and FTY720-, Imatinib-, and 1,9-dideoxyforskolin–
treated 32D-p210BCR/ABL (wild-type and T315I), K562, BaF3-p190BCR/ABL, CML-BCCD34+ (n = 3), and Ph1 ALLCD34+/CD19+ cells (n = 
6). Grb2 protein levels were detected as control for equal loading.  
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to suppress the phosphatase activity of PP2A. 
To further demonstrate that the FTY720-induced suppression of BCR/ABL 
activity and expression depends on activation of PP2A, parental and BCR/ABL-
expressing 32Dcl3 cells were transduced with a retrovirus (pBABE-GFP-sTAg) 
carrying the PP2A inhibitor SV40 small-t antigen. Expression of small-t (Figure 7B) 
abrogated the effects of FTY720; in fact, FTY720 treatment was unable to rescue 
to suppress BCR/ABL activity or expression (Figure 7B) in GFP+ small-t-
expressing 32D-BCR/ABL cells.  
While imatinib treatment suppresses wild-type BCR/ABL kinase activity only 
(Figure 7C, lanes 1 and 2), enhanced PP2A activity by FTY720 treatment 
abolished p210BCR/ABL phosphorylation and induced its downregulation in imatinib-
sensitive (32D-p210BCR/ABL and K562) and -resistant (T315I) cell lines (Figure 2B, 
lanes 3–8) and in primary CML-BCCD34+ cells (Figure 7C, lanes 12 and 13). The 
PP2A-mediated effects of FTY720 were also clearly evident in the lymphoid BaF3-
p190BCR/ABL cell line and Ph1 ALLCD34+/CD19+ patient cells. In fact, p190BCR/ABL 
tyrosine phosphorylation and expression were strongly inhibited in BaF3-
p190BCR/ABL and IL-7-cultured Ph1 ALLCD34+/CD19+ cells treated with FTY720 (Figure 
7C, lanes 9-11, 14, and 15). Likewise, 1,9-dideoxyforskolin, a PP2A activator 
capable of impairing p210-BCR/ABL expression and leukemogenesis (62), 
efficiently suppressed p190-BCR/ABL activity and expression in BaF3-p190BCR/ABL 
(Figure 7C, lane 10) and Ph1 ALLCD34+/CD19+ cells.  
Antileukemic activity of FTY720 in Ph1 leukemia cells in vitro 
To assess the biologic effects and therapeutic relevance of FTY720 in Ph1 
leukemias, primary bone marrow progenitors from imatinib-sensitive and -resistant 
CML-BC, imatinib-sensitive and -resistant CML-CP, and Ph1 ALL patients were 
treated with 2.5 ⎧M FTY720 for 48–96 hours and used to assess apoptosis and/or 
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clonogenic potential. For controls we used normal CD34+ and CD34+/CD19+ 
progenitors (NBM) treated with FTY720 at the same conditions. Consistent with its 
ability to strongly enhance PP2A activity in Ph1 but not in normal hematopoietic 
progenitors (Figure 7A), FTY720 markedly induced apoptosis (Figure 4) of IL-3/IL-
6/Flt-3L/SCF-cultured and IL-7/Flt-3L/SCF-cultured CML-BCCD34+ and Ph1 
ALLCD34+/CD19+ patient cells. A similar proapoptotic effect was observed in CML-
CPCD34+ cells treated with FTY720 (Figure 8). In fact, the percentage of apoptosis 
(annexin V+ cells) in FTY720-treated primary CML-BCCD34+ and CML-CPCD34+ cells 
ranged between 86% and 97% (Figure 8). FTY720-treated and Ph1 ALLCD34+/CD19+ 
cells also underwent marked cell death (98% annexin V+ cells) (Figure 8). By 
contrast, the percentages of apoptotic NBMCD34+, and NBMCD34+/CD19+ cells were 
not significantly altered in FTY720-treated cells compared with untreated cells 
(Figure 8). Because inhibition of the BCR/ABL-dependent PI3K/Akt pathway 
triggers caspase-dependent apoptosis (7), strong activation of caspase-3/7 was 
Figure 8. Caspase-3/7 (graphs) and annexin-V/propidium iodide (annexin-V/PI) (flow cytometry dot plots) assays in untreated 
and FTY720- treated (2.5 μM) NBMCD34+ (n = 3), CML-CPCD34+ (n = 3), CML-BCCD34+ (n = 3) and NBMCD34+/CD19+ (n = 3), Ph1 
ALLCD34+/CD19+ (n = 3) cells 
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observed in FTY720-treated CML-BCCD34+, CML-CPCD34+, and Ph1 ALLCD34+/CD19+ 
cells (an average of 6-fold increase) but not in normal hematopoietic progenitors 
(Figure 8). 
Similar to the inhibitory effect of forskolin or ectopic PP2Ac expression on 
colony formation of CML-BCCD34+ patient cells (62), a single dose of FTY720 
strongly abolished (80%–95% inhibition) the ability of primary imatinib-sensitive 
and Imatinib- and Dasatinib-resistant CML-BCCD34+ and CML-CPCD34+ marrow cells 
to form IL-3-derived colonies in semisolid medium (Figure 9A). Also, IL-7-driven 
colony formation of Ph1 ALLCD34+/CD19+ lymphoid progenitors was dramatically 
suppressed (an average of 80% inhibition) by exposure to 2.5 ⎧M FTY720. 
Moreover, the presence of malignant cells bearing the Imatinib and Dasatinib-
resistant T315I BCR/ABL mutant did not influence the responsiveness of bone 
marrow CD34+ CML-CP or CML-BC cells to FTY720 (Figure 9A). Conversely, 
Figure 9. A: IL-3- (for myeloid progenitors) and IL-7-dependent (for lym- phoid progenitors) colony-forming ability (mean ± SD) 
of untreated and FTY720-treated NBMCD34+ (n = 4), CML-CPCD34+ (n = 3), CML-BCCD34+ (n = 11), CML-CPCD34+ (T315I) (n = 1), 
CML-BCCD34+ (T315I) (n = 3), NBMCD34+/CD19+ (n = 4), and Ph1 ALLCD34+/CD19+ (n = 12) cells. As controls, 100% clonogenic 
potential was attributed to the IL-3- and IL-7-driven colony formation of NBMCD34+ and NBMCD34+/CD19+, respectively. B: Inhibition 
of PP2A activity by okadaic acid (0.25 nM) rescues the clonogenic potential of FTY720-treated CML-CPCD34+, CML-BCCD34+, 
and Ph1 ALLCD34+/CD19+ cells 
 
 39
FTY720 did not affect the IL-3- or IL-7-driven clonogenic potential of NBMCD34+ or 
NBMCD34+/CD19+ cells, respectively. Consistent with the important role of PP2A as 
mediator of the in vitro cytotoxic effect of FTY720, co-treatment with 2.5 ⎧M 
FTY720 and 0.25 nM okadaic acid significantly rescued cytokine-dependent colony 
formation of CML-CPCD34+, CML-BCCD34+, and Ph1 ALLCD34+/CD19+ bone marrow 
progenitors (Figure 9B). 
FTY720 suppresses in vivo BCR/ABL leukemogenesis 
To assess the effect of FTY720 on an in vivo model of CML and Ph1 ALL we used 
SCID mice that were intravenously injected with 32D-p210BCR/ABL, BaF3-
p190BCR/ABL, or 32D-p210BCR/ABL (T315I) cells (5⋅105 cells/mouse). Seven days post-
injection, cell engraftment was assessed by the presence of circulating BCR/ABL+ 
cells via nested RT-PCR–mediated detection of p210 or p190 BCR/ABL transcripts 
in peripheral blood (PB) (Figure 10A). Intra-peritoneal treatment with FTY720 (10 
mg/kg/d; LD50 [50% lethal dose] = 300 mg/kg) was then initiated in 13 mice per 
group (n = 39). As controls, 13 untransplanted mice received daily treatment with 
FTY720, whereas an identical number of cell-injected mice were left untreated. 
After 4 weeks of FTY720 treatment, all treated leukemic mice were alive and 
BCR/ABL negative (Figure 10A), whereas only 3-4 untreated leukemic mice were 
alive but appeared lethargic and were BCR/ABL positive (Figure 10A). Thus, 3 
mice per group were sacrificed and organs were evaluated by visual inspection 
and light microscopy. Mice injected with wild-type or T315I p210 and p190 
BCR/ABL+ cells showed massive splenomegaly, whereas, the morphology of 
spleens from FTY720-treated BCR/ABL+ cell-injected mice resembled that of 
control age-matched or FTY720-only treated mice (Figure 10A). Peripheral blood 
cytospins and hematoxylin and eosin-stained sections of spleen, bone marrow, 
and liver of 32D-p210BCR/ABL, 32D-p210BCR/ABL (T315I), and BaF3-p190BCR/ABL mice 
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Figure 10. Pharmacologic doses of FTY720 impair in vivo imatinib/dasatinib-sensitive and -resistant p210 and p190 BCR/ABL 
leukemogenesis. (A) Left: Nested RT-PCR for p210 and p190 BCR/ABL indicates the presence of BCR/ABL-expressing cells in the 
PB of untreated and FTY720-treated mice. Nested RT-PCR performed with RNA from PB of mice treated with FTY720 only (far right 
lane) and with RNA from a 1:106 dilution of K562 or BaF3p190 (BCR/ABL+ cells) with 32Dcl3 cells were used, respectively as 
negative and positive controls. GAPDH mRNA levels were used as a control. Right panel: Visual analysis of spleens from age-
matched and FTY720-treated mice and untreated and FTY720-treated mice injected with the indicated cell lines. (B) May-
Grumwald/Giemsa staining of PB and H&E staining of sections from bone marrow, spleen, and liver of untreated and FTY720-treated 
(4 weeks) control and cell-injected mice. Original magnification, ×400 (PB and bone marrow); ×250 (liver and spleen). (C) Effect of 10 
mg/kg/d FTY720 on survival of SCID mice i.v. injected with the indicated cells lines (n = 13; orange lines). Mice injected with cells 
only (n = 13; blue lines) or drug only (n = 13; green lines) were used as controls. The red lines below each graph indicate the 
treatment regimen. Survival was calculated by the Kaplan-Meier method, and the log-rank test evaluated the differences among 
survival distributions. Overall, P < 0.0001; 32D-p210BCR/ABL untreated versus FTY720-treated, P < 0.0001; 32D-p210BCR/ABL (T315I) 
untreated versus FTY720-treated, P < 0.001; and BaF3-p190BCR/ABL untreated versus FTY720-treated, P < 0.0001. 
 41
treated with vehicle (saline solution) showed extensive infiltration of blast cells with 
a low degree of myeloid maturation and presence of a large number of circulating 
blast cells typical of an overt acute myeloid leukemia-like process (Figure 10B). In 
contrast, spleen, liver, and bone marrow histopathology and peripheral blood from 
the FTY720-treated leukemic mice (Figure 10B) were similar to that of the age-
matched and FTY720-injected control groups (Figure 10B). Consistent with these 
findings, 80% and 90% of FTY720-treated mice injected with 32D-p210BCR/ABL or 
BaF3-p190BCR/ABL cells, respectively, were BCR/ABL-negative at 16 weeks (Figure 
10A) and all were alive 27 weeks (6.3 months) after transplant (Figure 10C). By 
contrast, the median survival of mice injected with 32D-p210BCR/ABL or BaF3-
p190BCR/ABL cells, only was 4.3 and 4.1 weeks, respectively (Figure 10C). Similarly, 
all untreated 32D-p210BCR/ABL (T315I) mice died within 5 weeks (median survival, 
4.8 weeks) (Figure 10C), while 80% of FTY720-treated T315I mice were alive after 
8 weeks of treatment. As expected, all of the control mice were still alive after 27 
weeks of daily treatment with FTY720 (10 mg/kg) (Figure 10C). Importantly, no 
signs of toxicity were observed in control or cell-injected SCID mice that received 
10 mg/kg FTY720 for 27 weeks.  
FTY720 induces apoptosis of the CML Leukemia Initiating Cells 
There is increasing evidence that the Leukemia Initiating Cells in CML are 
resistant to treatment by tyrosine kinase inhibitors (97). According to the “Cancer 
Stem Cell Hypothesis” the persistence of a small pool of cells capable of self-
propagation (self-renewal) could ultimately lead to relapse of the malignancy (115). 
In light of these recent findings we have sought to determine whether PP2A may 
have a role also in the stem cell compartment of both CML-CP and -BC. Indeed we 
have found that SET-dependent suppression of PP2A activity is a common feature 
of BCR/ABL+ CD34+/CD38- hematopoietic stem cells (HSC) and of 
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Figure 11: A: levels of intracellular SET staining expressed as mean of fluorescence intensity (MFI) in the HSC/CMP/GMP 
fractions from CML-BC and NBM cells. Levels of intracellular phospho-Crkl were detected as readout for BCR/ABL activity.  B: 
effect of FTY720 on the clonogenic potential of HSC and GMP from CML-BC cells. C: CML-BCCD34+ cells were exposed to 
Imatinib, Dasatinib of FTY720 for one week, then assayed for primitive HSC in long-term cultures for 5 weeks. Frequency of 
LTC-ICs is expressed as a percentage of the CFC output. D: CML-BCCD34+ and NBMCD34+ were stained with CFSE and were left 
untreated, treated with Imatinib, Dasatinib of FTY720, the numbers represent the percentage of quiescent CFSEmax/CD34+ 
input cells, which did not undergo any cell divisions over the time in culture. E: flowcytometric analysis of the effects of Imatinib, 
Dasatinib and FTY720 on the number of CML-BC quiescent CFSEmax cells, on the levels (MFI) of BCR/ABL activity 
(expressed as MFI of pABL staining) and on the induction of apoptosis in CFSEmax, expressed as percentage of Annexin V+. 
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CD34+/CD38+/CD45Rα- Granulocyte-Macrophage Progenitors (GMP, the 
candidate leukemic stem cell in Blast Crisis (76)) but not of the equivalent cell 
fractions from healthy individuals (Figure 11A). To determine the biological 
importance and therapeutic implications of impaired PP2A activity in Philadelphia-
chromosome stem cells, we evaluated by clonogenic, CFC/replating, LTC-IC and 
CFSE-mediated cell division-tracking assays, the effects of FTY720, or ectopic 
PP2Ac expression on survival and self-renewal of BCR/ABL+ stem/progenitor cells 
isolated from bone marrow of CML-CP and -BC patients. FTY720 treatment 
severely suppressed the clonogenic potential of CD34+/CD38- and 
CD34+/CD38+/CD45Rα- CML stem/progenitor cells (Figure 11B). Accordingly, 
self-renewal and long-term repopulating potential of CML leukemic stem cells was 
markedly impaired by pharmacologic PP2A reactivation. In fact, the CFC output of 
LTC-IC cultures (6 weeks) deriving from FTY720-treated CML CD34+ cells was 
greatly inhibited if compared to that of LTC-IC cultures from untreated CML cells 
(Figure 11C). By contrast, imatinib and dasatinib treatment led to increase or little 
change in CFC output.  Consistent with the ability of FTY720 to impair self-renewal 
of CML stem cells, a substantial reduction of the CFSEMAX/quiescent cell 
population was observed in CFSE-stained CD34+ CML cells treated for 6-9 days 
with FTY720 (Figure 11D). Notably, FTY720 did not exert any significant effect on 
CFSE-stained CD34+ cells from healthy individuals whereas, as expected, Imatinib 
and Dasatinib treatment led to an accumulation of CFSEMAX CML cells. 
Interestingly, only FTY720 triggered apoptosis of CFSEMAX CML cells (41% 
Annexin V+ cells) even though all of the treatments (Imatinib and Dasatinib 
included) efficiently inhibited BCR/ABL activity in CFSEMAX cells, suggesting that 
BCR/ABL-independent PP2A-regulated signals control the survival and self-
renewal of CML stem cells (Figure 11E).  
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DISCUSSION 
 
Because of the central role of PP2A in the regulation of cell growth, survival and 
differentiation, its loss-of-function most likely contributes to blastic transformation of 
CML and to emergence of Ph1 B-ALL. In this scenario, the BCR/ABL example of 
kinase-driven cancers may serve as a paradigm for those cancers characterized 
by exacerbated kinase activity and PP2A loss-of-function. In these tumors in which 
an oncogenic kinase is the key-player in promoting and sustaining the transformed 
phenotype, PP2A will have the role of a “gatekeeper”, as its activation may control 
and restrain the expression/activity of the oncogene itself (62). In contrast, 
inhibition of PP2A allows increased oncogene activity and induces a cascade of 
events that may promote disease development and progression by enhancing 
survival, proliferation and self-renewal, impairing differentiation and increasing 
genomic instability of the transformed cell clone (Figure 12).  
Figure 12. Schematic representation of the BCR/ABL-dependent inhibition of PP2A (left), and of the hypothesis that by 
reactivating PP2A activity through brug treatment it may be possible to interfere with the activity of the BCR/ABL oncoproteins 
and, as a consequence,antagonize the leukemic phenotype. 
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In this study we provide evidence supporting the therapeutic use of drugs 
that activate PP2A, and specifically FTY720 in Imatinib/Dasatinib-sensitive and -
resistant CML-BC and also Ph1 ALL. Specifically, we demonstrate that growth 
inhibition and induction of caspase-dependent apoptosis by FTY720 depend on 
interference with p210 and p190 BCR/ABL oncogenic activity. In fact, the FTY720 
antiproliferative and proapoptotic effects are preceded by a marked decrease of 
p210/p190 BCR/ABL activity and expression. 
Consistent with the role of PP2A as mediator of the FTY720 effects in Ph1 
leukemic progenitors, it has been reported that FTY720 activates PP2A through 
interaction with purified PP2A/AC dimers (111) and that rescue of PP2A activity 
induces the SHP-1-dependent p210-BCR/ABL dephosphorylation and 
proteasome-dependent degradation (62). Furthermore, the evidence that SV40 
small-t prevents the FTY720-induced BCR/ABL inactivation and degradation, 
together with the ability of picomolar concentrations of okadaic acid to rescue the 
clonogenic potential of CD34+ CML-CP, CML-BC, and Ph1 ALL progenitors and 
restore both activity and expression of BCR/ABL in FTY720- and 1,9-
dideoxyforskolin–treated (26) BCR/ABL+ cells strongly indicates that FTY720 
functions through activation of PP2A.  
In p210 and p190 BCR/ABL-expressing myeloid and lymphoid cell lines and 
in patient-derived primary CD34+ CML-CP and -BC and Ph1 ALLCD34+/CD19+ bone 
marrow progenitors, PP2A activation by FTY720 resulted in marked induction of 
apoptosis and inhibition of cytokine-dependent clonogenic potential regardless of 
the expression of a wild-type or T315I BCR/ABL oncoprotein. Conversely, no 
effects were observed in primary myeloid and lymphoid bone marrow CD34+ and 
CD34+/CD19+ progenitors from healthy individuals. In addition, we show that daily 
administration of FTY720 for 27 weeks in SCID mice efficiently impaired p210 
(wild-type and T315I) and p190 BCR/ABL leukemogenesis without inducing 
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adverse effects in vivo in hematopoietic and non-hematopoietic organs. In fact, 
80%, 50%, and 90% of FTY720-treated mice injected with 32D-p210BCR/ABL, 32D-
p210BCR/ABL (T315I), and BaF3-p190BCR/ABL cells, respectively, were alive and with 
no molecular signs of leukemia after FTY720 treatment.  
In summary, because of the central role of PP2A in the regulation of cell 
growth, survival, and differentiation, it is clear that its loss of function is essential 
for the development and maintenance of CML-BC and Ph1 ALL. Moreover, the 
knowledge that functional inactivation of PP2A tumor suppressor activity occurs in 
myeloid BC CML and Ph1 ALL through the effect of p210 and p190 BCR/ABL on 
SET expression and that pharmacologic reestablishment of normal PP2A activity 
antagonizes both in vitro and in vivo BCR/ABL leukemogenesis, highlights the 
importance of incorporating PP2A-activating drugs into the current therapeutic 
protocols for those Ph1 leukemias that are nonresponsive or develop resistance to 
Imatinib, Nilotinib, and/or Dasatinib. Our data, supports the use of this PP2A 
activator as a novel therapeutic approach for treatment of CML-BC and Ph1 ALL 
patients who are unresponsive to current kinase inhibitor therapy and, perhaps, for 
treatment of other cancers characterized by functional loss of PP2A activity. 
Moreover our most recent preliminary data support the idea that inactivation 
of PP2A may be an early event that occur in the Leukemia Initiating Cells in CML-
CP and CML-BC; these are known to be refractory to the treatment with the 
currently developed tyrosine kinase inhibitors. Therefore treatment with PP2A-
activating drugs, such as FTY720, may also have the potential of fully eradicating 
the disease by targeting a small population of leukemic cells that, if left untouched, 
is fully capable of re-initiate the leukemia and induce relapse. 
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